Neeraj Sharma, CEO and Managing Director, OneSource Specialty Pharma, outlines, The global market for GLP1based therapies is experiencing unprecedented growth, given the increasing incidence of Type 2 diabetes and obesity and its efficacy in the management of both diseases
Petter Bjornstad has acted as a consultant for Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, Novo Nordisk and Horizon Pharma
Abstract Introduction Glucagon-like peptide-1 receptor agonist use has increased over the last decade for glycemic control in type 2 diabetes mellitus, cardiovascular risk reduction, and weight loss
Half had taken GLP-1s for five years, and half hadnt
Acetyl-L-carnitine has demonstrated many health-promoting effects, including the following: an increase in mental and physical energy an improvement in heart and brain function an improvement in concentration levels and memory an improvement in general mood protection of neurons and a reduction of damage by free radicals a reduction of the formation of amyloid plaque it contributes to the maintenance and restoration of the myelin of the nerve sheaths it can decrease symptoms of peripheral neuropathy in diabetics it can enhance male fertility Acetyl-L-carnitine has also shown that it increases the neurotransmitters norepinephrine and serotonin, causing an improvement in depressive conditions
